MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, has announced a new collaboration with Johnson & Johnson Innovation and its affiliate Janssen, Inc., in Canada to advance early-stage technologies related to human health in therapeutics, medical devices, and diagnostics. Through the collaboration, MaRS Innovation and technical experts from the Johnson & Johnson Innovation Center in Boston will jointly identify and fund high-potential opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, which include the University of Toronto and its affiliated teaching hospitals.
“We are looking forward to working with Johnson & Johnson Innovation,” said Dr. Raphael Hofstein, president and CEO, MaRS Innovation. “There are many high quality opportunities coming out of the Toronto research community, and these opportunities can benefit from our close collaboration.”
Through the agreement, Johnson & Johnson Innovation will provide funding over a three-year period to support promising individual projects based on joint due diligence, which will be leveraged with financial support from MaRS Innovation. The fund will accelerate the development and validation of healthcare technologies within one of Canada’s highly innovative academic clusters.